AnaptysBio Inc (ANAB) to Post FY2021 Earnings of ($5.67) Per Share, Jefferies Group Forecasts

AnaptysBio Inc (NASDAQ:ANAB) – Jefferies Group reduced their FY2021 earnings per share estimates for AnaptysBio in a research note issued on Monday. Jefferies Group analyst B. Amin now expects that the biotechnology company will post earnings of ($5.67) per share for the year, down from their prior estimate of ($5.14). Jefferies Group currently has a “Buy” rating and a $145.00 target price on the stock.

Other equities research analysts also recently issued reports about the company. SunTrust Banks lifted their price objective on AnaptysBio from $115.00 to $162.00 and gave the stock a “buy” rating in a report on Thursday, February 15th. Robert W. Baird restated a “buy” rating and set a $144.00 price objective (up from $81.00) on shares of AnaptysBio in a report on Friday, January 19th. Zacks Investment Research upgraded AnaptysBio from a “sell” rating to a “hold” rating and set a $74.00 price objective on the stock in a report on Friday, November 10th. ValuEngine upgraded AnaptysBio from a “sell” rating to a “hold” rating in a report on Friday, February 2nd. Finally, Wedbush restated an “outperform” rating and set a $142.00 price objective on shares of AnaptysBio in a report on Tuesday. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. AnaptysBio has an average rating of “Buy” and an average price target of $118.67.

AnaptysBio (NASDAQ ANAB) traded up $0.02 during mid-day trading on Thursday, reaching $121.05. The company’s stock had a trading volume of 105,500 shares, compared to its average volume of 299,331. The company has a quick ratio of 10.77, a current ratio of 10.77 and a debt-to-equity ratio of 0.09. AnaptysBio has a 52 week low of $18.15 and a 52 week high of $134.00. The stock has a market cap of $2,880.00 and a P/E ratio of -81.95.

Several institutional investors and hedge funds have recently modified their holdings of the company. MetLife Investment Advisors LLC acquired a new position in shares of AnaptysBio in the 4th quarter worth approximately $830,000. Redmile Group LLC acquired a new position in shares of AnaptysBio in the 4th quarter worth approximately $23,150,000. Jane Street Group LLC acquired a new position in shares of AnaptysBio in the 4th quarter worth approximately $382,000. TIAA CREF Investment Management LLC grew its position in shares of AnaptysBio by 144.7% in the 4th quarter. TIAA CREF Investment Management LLC now owns 103,430 shares of the biotechnology company’s stock worth $10,417,000 after acquiring an additional 61,166 shares in the last quarter. Finally, Teachers Advisors LLC grew its position in shares of AnaptysBio by 54.0% in the 4th quarter. Teachers Advisors LLC now owns 32,666 shares of the biotechnology company’s stock worth $3,290,000 after acquiring an additional 11,456 shares in the last quarter. Institutional investors own 95.56% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “AnaptysBio Inc (ANAB) to Post FY2021 Earnings of ($5.67) Per Share, Jefferies Group Forecasts” was originally posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are accessing this article on another website, it was copied illegally and republished in violation of US and international copyright and trademark laws. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/02/22/anaptysbio-inc-anab-to-post-fy2021-earnings-of-5-67-per-share-jefferies-group-forecasts.html.

About AnaptysBio

AnaptysBio, Inc is a United States-based biotechnology company. The Company is engaged in developing antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology. The Company develops its product candidates using its antibody discovery technology platform, which is designed to replicate, in vitro, the natural process of antibody generation.

Earnings History and Estimates for AnaptysBio (NASDAQ:ANAB)

Receive News & Ratings for AnaptysBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AnaptysBio and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply